1、 CHIANG J Y.Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism[J].Expert Opin Drug Metab Toxicol,2009,5(2):137-147. CHIANG J Y.Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism[J].Expert Opin Drug Metab Toxicol,2009,5(2):137-147.
2、 SHIH D Q,BUSSEN M,SEHAYEK E,et al.Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabo lism[J].Nat Genet,2001,27(4):375-382. SHIH D Q,BUSSEN M,SEHAYEK E,et al.Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabo lism[J].Nat Genet,2001,27(4):375-382.
3、 CHOW E C,MAGOMEDOVA L,QUACH H P,et al.Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol[J].Gastroenterology,2014,146(4):1048-1059. CHOW E C,MAGOMEDOVA L,QUACH H P,et al.Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol[J].Gastroenterology,2014,146(4):1048-1059.
4、 GONZALEZ-SANCHEZ E,EL MOURABIT H,JAGER M,et al.Cholangiopathy aggravation is caused by VDR ablation and alleviated by VDR-independent vitamin D signaling in ABCB4 knockout mice[J].Biochim Biophys Acta Mol Basis Dis,2021,1867(4):166067. GONZALEZ-SANCHEZ E,EL MOURABIT H,JAGER M,et al.Cholangiopathy aggravation is caused by VDR ablation and alleviated by VDR-independent vitamin D signaling in ABCB4 knockout mice[J].Biochim Biophys Acta Mol Basis Dis,2021,1867(4):166067.
5、 GABBIA D,POZZA A D,ALBERTONI L,et al.Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis[J].World J Gastroenterol,2017,23(42):7519-7530. GABBIA D,POZZA A D,ALBERTONI L,et al.Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis[J].World J Gastroenterol,2017,23(42):7519-7530.
6、 STERN S,KURIAN R,WANG H.Clinical relevance of the constitutive androstane receptor[J].Drug Metab Dispos,2022,50(7):1010-1018. STERN S,KURIAN R,WANG H.Clinical relevance of the constitutive androstane receptor[J].Drug Metab Dispos,2022,50(7):1010-1018.
7、 THIBAUT M M,BINDELS L B.Crosstalk between bile acid-activated receptors and microbiome in entero-hepatic inflammation[J].Trends Mol Med,2022,28(3):223-336. THIBAUT M M,BINDELS L B.Crosstalk between bile acid-activated receptors and microbiome in entero-hepatic inflammation[J].Trends Mol Med,2022,28(3):223-336.
8、 XIAO Y,ZHOU K,LU Y,et al.Administration of antibiotics contributes to cholestasis in pediatric patients with intestinal failure via the alteration of FXR signaling[J].Exp Mol Med,2018,50(12):1-14. XIAO Y,ZHOU K,LU Y,et al.Administration of antibiotics contributes to cholestasis in pediatric patients with intestinal failure via the alteration of FXR signaling[J].Exp Mol Med,2018,50(12):1-14.
9、 ZHU Y,LI F,GUO G L.Tissue-specific function of farnesoid X receptor in liver and intestine[J].Pharmacol Res,2011,63(4):259-265. ZHU Y,LI F,GUO G L.Tissue-specific function of farnesoid X receptor in liver and intestine[J].Pharmacol Res,2011,63(4):259-265.
10、 WICHMAN B E,NILSON J,GOVINDAN S,et al.Beyond lipids:Novel mechanisms for parenteral nutrition-associated liver disease[J].Nutr Clin Pract,2022,37(2):265-273. WICHMAN B E,NILSON J,GOVINDAN S,et al.Beyond lipids:Novel mechanisms for parenteral nutrition-associated liver disease[J].Nutr Clin Pract,2022,37(2):265-273.
11、 MEMON N,GRIFFIN I J,LEE C W,et al.Developmental regulation of the gut-liver(FGF19-CYP7A1)axis in neonates[J].J Matern Fetal Neonatal Med,2020,33(6):987-992. MEMON N,GRIFFIN I J,LEE C W,et al.Developmental regulation of the gut-liver(FGF19-CYP7A1)axis in neonates[J].J Matern Fetal Neonatal Med,2020,33(6):987-992.
12、 MOLINARO A,MARSCHALL H U.Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders[J].Biochem Soc Trans,2022,50(1):361-373. MOLINARO A,MARSCHALL H U.Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders[J].Biochem Soc Trans,2022,50(1):361-373.
13、 SULTAN M,RAO A,ELPELEG O,et al.Organic solute transporter-beta(SLC51B)deficiency in two brothers with congenital diarrhea and features of cholestasis[J].Hepatology,2018,68(2):590-598. SULTAN M,RAO A,ELPELEG O,et al.Organic solute transporter-beta(SLC51B)deficiency in two brothers with congenital diarrhea and features of cholestasis[J].Hepatology,2018,68(2):590-598.
14、 GAO E,CHEEMA H,WAHEED N,et al.Organic solute transporter alpha deficiency:a disorder with cholestasis,liver fibrosis,and congenital diarrhea[J].Hepatology,2020,71(5):1879-1882. GAO E,CHEEMA H,WAHEED N,et al.Organic solute transporter alpha deficiency:a disorder with cholestasis,liver fibrosis,and congenital diarrhea[J].Hepatology,2020,71(5):1879-1882.
15、 LI M,WANG Q,LI Y,et al.Apical sodium-dependent bile acid transporter,drug target for bile acid related diseases and delivery target for prodrugs:Current and future challenges[J].Pharmacol Ther,2020(212):107539. LI M,WANG Q,LI Y,et al.Apical sodium-dependent bile acid transporter,drug target for bile acid related diseases and delivery target for prodrugs:Current and future challenges[J].Pharmacol Ther,2020(212):107539.
16、 ANNABA F,SARWAR Z,GILL R K,et al.Enteropathogenic Escherichia coli inhibits ileal sodium-dependent bile acid transporter ASBT[J].Am J Physiol Gastrointest Liver Physiol,2012,302(10):G1216-1222. ANNABA F,SARWAR Z,GILL R K,et al.Enteropathogenic Escherichia coli inhibits ileal sodium-dependent bile acid transporter ASBT[J].Am J Physiol Gastrointest Liver Physiol,2012,302(10):G1216-1222.
17、 CHOTHE P P,CZUBA L C,AYEWOH E N,et al.Tyrosine phosphorylation regulates plasma membrane expression and stability of the human bile acid transporter ASBT(SLC10A2)[J].Mol Pharm,2019,16(8):3569-3576. CHOTHE P P,CZUBA L C,AYEWOH E N,et al.Tyrosine phosphorylation regulates plasma membrane expression and stability of the human bile acid transporter ASBT(SLC10A2)[J].Mol Pharm,2019,16(8):3569-3576.
18、 PABLO ARAB J,CABRERA D,ARRESE M.Bile acids in cholestasis and its treatment[J].Annals of Hepatology,2017,16(Suppl 1):S53-S57. PABLO ARAB J,CABRERA D,ARRESE M.Bile acids in cholestasis and its treatment[J].Annals of Hepatology,2017,16(Suppl 1):S53-S57.
19、 MIETHKE A G,ZHANG W,SIMMONS J,et al.Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice[J].Hepatology,2016,63(2):512-523. MIETHKE A G,ZHANG W,SIMMONS J,et al.Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice[J].Hepatology,2016,63(2):512-523.
20、 HEGADE V S,JONES D E,HIRSCHFIELD G M.Apical sodium-dependent transporter inhibitors in primary biliary cholangitis and primary sclerosing cholangitis[J].Dig Dis,2017,35(3):267-274. HEGADE V S,JONES D E,HIRSCHFIELD G M.Apical sodium-dependent transporter inhibitors in primary biliary cholangitis and primary sclerosing cholangitis[J].Dig Dis,2017,35(3):267-274.
21、 CAREY A N,ZHANG W,SETCHELL K D R,et al.Hepatic MDR3 expression impacts lipid homeostasis and susceptibility to inflammatory bile duct obstruction in neonates[J].Pediatr Res,2017,82(1):122-32. CAREY A N,ZHANG W,SETCHELL K D R,et al.Hepatic MDR3 expression impacts lipid homeostasis and susceptibility to inflammatory bile duct obstruction in neonates[J].Pediatr Res,2017,82(1):122-32.
22、 MORAIS M B,MACHADO M V.Benign inheritable disorders of bilirubin metabolism manifested by conjugated hyperbilirubinemia-A narrative review[J].United European Gastroenterol J,2022,10(7):745-753. MORAIS M B,MACHADO M V.Benign inheritable disorders of bilirubin metabolism manifested by conjugated hyperbilirubinemia-A narrative review[J].United European Gastroenterol J,2022,10(7):745-753.
23、 曹敏玲. 青少年ABCB11基因突变相关肝内胆汁淤积症临床特征分析[J].中国优生与遗传杂志,2021,29(12):1730-1734. 曹敏玲. 青少年ABCB11基因突变相关肝内胆汁淤积症临床特征分析[J].中国优生与遗传杂志,2021,29(12):1730-1734.
24、 田媛媛,刘梅,熊晶晶,等.ABCB11基因突变致暂时性新生儿胆汁淤积症1例病例报告[J].中国循证儿科杂志,2019,14(2):149-151. 田媛媛,刘梅,熊晶晶,等.ABCB11基因突变致暂时性新生儿胆汁淤积症1例病例报告[J].中国循证儿科杂志,2019,14(2):149-151.
25、 STICOVA E,LODEREROVA A,van de STEEG E,et al.Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis[J].Int J Clin Exp Pathol,2015,8(5):5252-5262. STICOVA E,LODEREROVA A,van de STEEG E,et al.Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis[J].Int J Clin Exp Pathol,2015,8(5):5252-5262.
26、 SUGA T,YAMAGUCHI H,SATO T,et al.Preference of conjugated bile acids over unconjugated bile acids as substrates for OATP1B1 and OATP1B3[J].PLoS One,2017,12(1):e0169719. SUGA T,YAMAGUCHI H,SATO T,et al.Preference of conjugated bile acids over unconjugated bile acids as substrates for OATP1B1 and OATP1B3[J].PLoS One,2017,12(1):e0169719.
27、 TOTH B,JANI M,BEERY E,et al.Human OATP1B1(SLCO1B1)transports sulfated bile acids and bile salts with particular efficiency[J].Toxicol In Vitro,2018(52):189-194. TOTH B,JANI M,BEERY E,et al.Human OATP1B1(SLCO1B1)transports sulfated bile acids and bile salts with particular efficiency[J].Toxicol In Vitro,2018(52):189-194.
28、 DENG L J,OUYANG W X,LIU R,et al.Clinical characterization of NTCP deficiency in paediatric patients :A case-control study based on SLC10A1 genotyping analysis[J].Liver Int,2021,41(11):2720-2728. DENG L J,OUYANG W X,LIU R,et al.Clinical characterization of NTCP deficiency in paediatric patients :A case-control study based on SLC10A1 genotyping analysis[J].Liver Int,2021,41(11):2720-2728.
29、 LU X,LIU L,SHAN W,et al.The role of the sodium-taurocholate co-transporting polypeptide(NTCP)and bile salt export pump(BSEP)in related liver disease[J].Curr Drug Metab,2019,20(5):377-389. LU X,LIU L,SHAN W,et al.The role of the sodium-taurocholate co-transporting polypeptide(NTCP)and bile salt export pump(BSEP)in related liver disease[J].Curr Drug Metab,2019,20(5):377-389.
30、 李晓峰,龚敬宇,王建设.胆汁酸的肠肝循环与胆汁淤积性肝病[J].临床肝胆病杂志,2017,33(10):1922-1927. 李晓峰,龚敬宇,王建设.胆汁酸的肠肝循环与胆汁淤积性肝病[J].临床肝胆病杂志,2017,33(10):1922-1927.
31、 刘笑,王琰.胆汁酸的合成调控及其在生理与病理中的功能机制[J].遗传,2019,41(5):365-374. 刘笑,王琰.胆汁酸的合成调控及其在生理与病理中的功能机制[J].遗传,2019,41(5):365-374.
32、 赵阳,王建华,胡晓明,等.128例新生儿胆汁淤积症临床病例特征回顾性分析[J].中华临床医师杂志(电子版),2019,13(5):321-325. 赵阳,王建华,胡晓明,等.128例新生儿胆汁淤积症临床病例特征回顾性分析[J].中华临床医师杂志(电子版),2019,13(5):321-325.
33、 MOYER V,FREESE D K,WHITINGTON P F,et al.Guideline for the evaluation of cholestatic jaundice in infants:recommendations of the North American Society for Pediatric Gastroenterology,Hepatology and Nutrition[J].J Pediatr Gastroenterol Nutr,2004,39(2):115-128. MOYER V,FREESE D K,WHITINGTON P F,et al.Guideline for the evaluation of cholestatic jaundice in infants:recommendations of the North American Society for Pediatric Gastroenterology,Hepatology and Nutrition[J].J Pediatr Gastroenterol Nutr,2004,39(2):115-128.
34、 陆伦根,蔡晓波,王建设,等.胆汁淤积性肝病管理指南(2021)[J].临床肝胆病杂志,2022,38(1):62-69. 陆伦根,蔡晓波,王建设,等.胆汁淤积性肝病管理指南(2021)[J].临床肝胆病杂志,2022,38(1):62-69.
